Prices delayed by at least 15 minutes | Print
Cidara Therapeutics (CDTX)
Common SharesThis share can be held in a Dealing accountISALifetime ISAJISASIPP
Company profile
Cidara Therapeutics Inc is a biotechnology company. It is focused on the discovery, development, and commercialization of novel anti-infectives for the treatment and prevention of diseases. The company's REZZAYO(R) (rezafungin for injection) is a novel molecule in the echinocandin class of antifungals. It is developing rezafungin for the first-line treatment and prevention of serious, invasive fungal infections which are associated with high mortality rates. Its other product candidates include CD377, CD388, RSV AVC, HIV AVC, and SARS-CoV-2 AVC.
Address
6310 Nancy Ridge Drive
Suite 101
San Diego
CA
USA
92121
Telephone
+1 858 752-6170
Forecast key dates
Name | Key Date |
---|---|
Cidara Therapeutics Inc Fourth Quarter Earnings Results for 2024 | 2025-04-22T00:00:00 |
Cidara Therapeutics Inc Annual Report for 2024 | 2025-04-22T00:00:00 |
Cidara Therapeutics Inc Third Quarter Earnings Results for 2024 | 2024-11-01T00:00:00 |
Cidara Therapeutics Inc Second Quarter Earnings Results for 2024 | 2024-08-02T00:00:00 |
Cidara Therapeutics Inc Annual General Meeting for 2024 | 2024-06-21T08:00:00 |
Cidara Therapeutics Inc First Quarter Earnings Results for 2024 | 2024-05-10T00:00:00 |
Previous key dates
Name | Key Date |
---|---|
Cidara Therapeutics Inc First Quarter Earnings Results for 2024 | 2024-05-10T00:00:00 |
Cidara will host a business strategy update conference | 2024-04-24T16:30:00 |
Cidara Therapeutics Inc Fourth Quarter Earnings Results for 2023 | 2024-04-22T00:00:00 |
Cidara Therapeutics Inc Annual Report for 2023 | 2024-04-22T00:00:00 |
Cidara Therapeutics Inc Third Quarter Earnings Results for 2023 | 2023-11-02T00:00:00 |
Cidara Therapeutics Inc Second Quarter Earnings Results for 2023 | 2023-08-03T00:00:00 |
Cidara Therapeutics Inc Annual General Meeting for 2023 | 2023-06-22T08:00:00 |
Cidara Therapeutics Inc First Quarter Earnings Results for 2023 | 2023-05-11T00:00:00 |
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2024 AJ Bell. All rights reserved.